• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ICU Medical Inc. (Amendment)

    2/9/23 11:22:19 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care
    Get the next $ICUI alert in real time by email
    SC 13G/A 1 tv01126-icumedicalinc.htm SCHEDULE 13G/A icumedicalinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  ICU Medical Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  44930G107

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  44930G107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    7,153

    7.  SOLE DISPOSITIVE POWER

    2,076,188

    8.  SHARED DISPOSITIVE POWER

    27,984

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,104,172

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    8.77%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ICU Medical Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    951 Calle Amanecer
    San Clemente, CA 92673-6212

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    44930G107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ICUI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICUI

    DatePrice TargetRatingAnalyst
    8/15/2025$145.00Overweight
    Piper Sandler
    3/12/2025$205.00 → $197.00Outperform → Strong Buy
    Raymond James
    12/11/2024$200.00Hold → Buy
    Jefferies
    10/14/2024$183.00Hold
    Jefferies
    6/21/2024Hold
    Needham
    6/17/2024$135.00Mkt Perform → Outperform
    Raymond James
    11/8/2022Outperform → Mkt Perform
    Raymond James
    2/28/2022$286.00 → $265.00Outperform
    Raymond James
    More analyst ratings

    $ICUI
    SEC Filings

    View All

    SEC Form S-8 filed by ICU Medical Inc.

    S-8 - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/8/25 4:05:53 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by ICU Medical Inc.

    10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:17:58 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:11:06 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICU Medical to Participate in Upcoming Investor Conferences

    SAN CLEMENTE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September: Wells Fargo 2025 Healthcare Conference on September 4, 2025 Company management will participate in a fireside chat at the Wells Fargo 2025 Healthcare Conference in Boston on Thursday, September 4, 2025. The discussion will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be webcast live on the Event Calendar section of the Company's Investor Relations website at https://ir.icumed.com. A replay of the webcast will be archived on the website for

    8/21/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

    Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

    5/17/23 4:40:03 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on ICU Medical with a new price target

    Piper Sandler initiated coverage of ICU Medical with a rating of Overweight and set a new price target of $145.00

    8/15/25 8:19:19 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Raymond James with a new price target

    Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously

    3/12/25 7:28:15 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Jefferies with a new price target

    Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00

    12/11/24 7:52:44 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    VP, General Counsel Sanzone Virginia Ruth sold $93,537 worth of shares (700 units at $133.62), decreasing direct ownership by 10% to 6,386 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/30/25 2:34:28 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Voigtlander Christian B. exercised 11,115 shares at a strike of $96.83 and sold $1,288,371 worth of shares (9,930 units at $129.75), increasing direct ownership by 24% to 6,088 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/28/25 12:00:55 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Leadership Updates

    Live Leadership Updates

    View All

    Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt

    11/27/23 6:28:00 PM ET
    $AVTA
    $BANC
    $CG
    Finance: Consumer Services
    Finance
    Major Banks
    Investment Managers

    $ICUI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/12/24 3:44:43 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/8/24 10:34:33 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.

    SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    7/18/24 7:06:07 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Financials

    Live finance-specific insights

    View All

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces First Quarter 2025 Results

    SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

    5/8/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care